Skip to main content
Journal cover image

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

Publication ,  Journal Article
Virani, SA; Dent, S; Brezden-Masley, C; Clarke, B; Davis, MK; Jassal, DS; Johnson, C; Lemieux, J; Paterson, I; Sebag, IA; Simmons, C; Thain, K ...
Published in: Can J Cardiol
July 2016

Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This guideline, authored by a pan-Canadian expert group of health care providers and commissioned by the Canadian Cardiovascular Society, is intended to guide the care of cancer patients with established cardiovascular disease or those at risk of experiencing toxicities related to cancer treatment. It includes recommendations and important management considerations with a focus on 4 main areas: identification of the high-risk population for cardiotoxicity, detection and prevention of cardiotoxicity, treatment of cardiotoxicity, and a multidisciplinary approach to cardio-oncology. All recommendations align with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Key recommendations for which the panel provides a strong level of evidence include: (1) that routine evaluation of traditional cardiovascular risk factors and optimal treatment of preexisting cardiovascular disease be performed in all patients before, during, and after receiving cancer therapy; (2) that initiation, maintenance, and/or augmentation of antihypertensive therapy be instituted per the Canadian Hypertension Educational Program guidelines for patients with preexisting hypertension or for those who experience hypertension related to cancer therapy; and (3) that investigation and management follow current Canadian Cardiovascular Society heart failure guidelines for cancer patients who develop clinical heart failure or an asymptomatic decline in left ventricular ejection fraction during or after cancer treatment. This guideline provides guidance to clinicians on contemporary best practices for the cardiovascular care of cancer patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Can J Cardiol

DOI

EISSN

1916-7075

Publication Date

July 2016

Volume

32

Issue

7

Start / End Page

831 / 841

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Troponin T
  • Risk Factors
  • Radiotherapy
  • Primary Prevention
  • Neoplasms
  • Natriuretic Peptide, Brain
  • Myocardial Ischemia
  • Magnetic Resonance Imaging, Cine
  • Hypertension
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Virani, S. A., Dent, S., Brezden-Masley, C., Clarke, B., Davis, M. K., Jassal, D. S., … Straatman, L. (2016). Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol, 32(7), 831–841. https://doi.org/10.1016/j.cjca.2016.02.078
Virani, Sean A., Susan Dent, Christine Brezden-Masley, Brian Clarke, Margot K. Davis, Davinder S. Jassal, Christopher Johnson, et al. “Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.Can J Cardiol 32, no. 7 (July 2016): 831–41. https://doi.org/10.1016/j.cjca.2016.02.078.
Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016 Jul;32(7):831–41.
Virani, Sean A., et al. “Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.Can J Cardiol, vol. 32, no. 7, July 2016, pp. 831–41. Pubmed, doi:10.1016/j.cjca.2016.02.078.
Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I, Sebag IA, Simmons C, Sulpher J, Thain K, Thavendiranathan P, Wentzell JR, Wurtele N, Côté MA, Fine NM, Haddad H, Hayley BD, Hopkins S, Joy AA, Rayson D, Stadnick E, Straatman L. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016 Jul;32(7):831–841.
Journal cover image

Published In

Can J Cardiol

DOI

EISSN

1916-7075

Publication Date

July 2016

Volume

32

Issue

7

Start / End Page

831 / 841

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Troponin T
  • Risk Factors
  • Radiotherapy
  • Primary Prevention
  • Neoplasms
  • Natriuretic Peptide, Brain
  • Myocardial Ischemia
  • Magnetic Resonance Imaging, Cine
  • Hypertension